Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2025-02-12 00:00:00 ET · period of report 2025-02-10 · accession 0000875320-25-000048 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-02-12 | 2025-02-10 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | F - Tax | $467.98 | -2,143 | 64.3K | -3% | -$1.00M | |
| 2025-02-12 | 2025-02-11 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $459.83 | -310 | 64.0K | -0.5% | -$142.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-10 | F | D | 2,143 | $467.98 | 64,331 | D | — | — | |
| 2 | Common | Common Stock | 2025-02-11 | S | D | 310 | $459.83 | 64,021 | D | — | — |